What does DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE do?

DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE is a specialist medical practice in Aalter. Private Limited, started on 16 July 2014, 1 establishment.

What is the address of DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE?

The registered office of DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE is located at Kestelstraat 75, 9880 Aalter.

Is DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE still active?

Yes. According to the CBE (29 September 2026) DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE is active, legal situation “Normale toestand”, started on 16 July 2014.

Is DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE registered on Peppol?

Yes, DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE is registered on the Peppol network with ID 0208:0556697054.

What is the enterprise number of DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE?

The enterprise number of DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE is BE0556697054.

When was DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE founded?

DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE was founded on 16 July 2014.

Who are the directors of DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE?

According to the 2025 annual accounts, the directors of DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE are: LEEN DE BACKER.

Is DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 16 July 2014; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE make in 2025?

DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE posted a profit after taxes of € 55,255 in financial year 2025.

What is the revenue of DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE?

As a small company, DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 81,753.

DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE (Private Limited)

Dossier DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE, printed on 29 September 2026 from databakkes.be/en/0556697054/dr-leen-de-backer-medische-oncologie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE from Aalter, company number BE0556697054, closed financial year 2025 with a result of € 55,255 after tax. For that financial year DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE recorded a gross margin of € 81,753 and equity of € 147,197. Compared with financial year 2024, the result moved from € 89,142 to € 55,255. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on April 27, 2026.

What it is worth Healthy

€ 147,197

▼ 23% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 55,255

▼ 38% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 113,908

▼ 59% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 100,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 43,833

▼ 22% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 1,372

▼ 81% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 23,273

▲ € 23,103 vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 189,089 Gross margin 2022: € 189,089 First fiscal year in the series	€ 134,528 Gross margin 2023: € 134,528 ▼ 29% vs 2022 (€ 189,089) Unfavourable step	€ 115,005 Gross margin 2024: € 115,005 ▼ 15% vs 2023 (€ 134,528) Unfavourable step	€ 81,753 Gross margin 2025: € 81,753 ▼ 29% vs 2024 (€ 115,005) Unfavourable step	▼ 29%
Profit after taxes	€ 144,929 Profit after taxes 2022: € 144,929 First fiscal year in the series	€ 103,648 Profit after taxes 2023: € 103,648 ▼ 28% vs 2022 (€ 144,929) Unfavourable step	€ 89,142 Profit after taxes 2024: € 89,142 ▼ 14% vs 2023 (€ 103,648) Unfavourable step	€ 55,255 Profit after taxes 2025: € 55,255 ▼ 38% vs 2024 (€ 89,142) Unfavourable step	▼ 38%
Equity	€ 316,350 Equity 2022: € 316,350 First fiscal year in the series	€ 419,999 Equity 2023: € 419,999 ▲ 33% vs 2022 (€ 316,350) Favourable step	€ 191,942 Equity 2024: € 191,942 ▼ 54% vs 2023 (€ 419,999) Unfavourable step	€ 147,197 Equity 2025: € 147,197 ▼ 23% vs 2024 (€ 191,942) Unfavourable step	▼ 23%
Total debts	€ 21,192 Total debts 2022: € 21,192 First fiscal year in the series	€ 14,858 Total debts 2023: € 14,858 ▼ 30% vs 2022 (€ 21,192) Favourable step	€ 288,202 Total debts 2024: € 288,202 ▲ € 273,344 vs 2023 (€ 14,858) Unfavourable step	€ 124,534 Total debts 2025: € 124,534 ▼ 57% vs 2024 (€ 288,202) Favourable step	▼ 57%
Cash	€ 63,649 Cash 2022: € 63,649 First fiscal year in the series	€ 44,680 Cash 2023: € 44,680 ▼ 30% vs 2022 (€ 63,649) Unfavourable step	€ 279,879 Cash 2024: € 279,879 ▲ € 235,198 vs 2023 (€ 44,680) Favourable step	€ 113,908 Cash 2025: € 113,908 ▼ 59% vs 2024 (€ 279,879) Unfavourable step	▼ 59%
Retained profit	€ 297,750 Retained profit 2022: € 297,750 First fiscal year in the series	€ 401,399 Retained profit 2023: € 401,399 ▲ 35% vs 2022 (€ 297,750) Favourable step	€ 173,342 Retained profit 2024: € 173,342 ▼ 57% vs 2023 (€ 401,399) Unfavourable step	€ 128,597 Retained profit 2025: € 128,597 ▼ 26% vs 2024 (€ 173,342) Unfavourable step	▼ 26%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 317,199 Dividend 2024: € 317,199 Unchanged (€ 0) Unchanged	€ 100,000 Dividend 2025: € 100,000 ▼ 68% vs 2024 (€ 317,199) Unchanged	▼ 68%
Balance sheet total	€ 337,543 Balance sheet total 2022: € 337,543 First fiscal year in the series	€ 434,856 Balance sheet total 2023: € 434,856 ▲ 29% vs 2022 (€ 337,543) Unchanged	€ 480,144 Balance sheet total 2024: € 480,144 ▲ 10% vs 2023 (€ 434,856) Unchanged	€ 271,731 Balance sheet total 2025: € 271,731 ▼ 43% vs 2024 (€ 480,144) Unchanged	▼ 43%

Key figures of DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE?

What happened at DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Apr 27, 2026 New annual accounts for financial year 2025: profit of € 55,255 (▼ 38% vs 2024). Source: NBB ↗
2023 LEEN DE BACKER became a director. NBB
Jul 17, 2014 New establishment in Tielt. KBO
Jul 16, 2014 Start of the company according to the CBE. KBO

In short

From € 144,929 profit in 2022 to € 55,255 profit in 2025.

Paid € 109,093 in corporate taxes since 2022.

Best year ever: 2022, with € 144,929 profit.

Paid out € 417,199 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE? We notify you, reason included.

Follow DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

LEEN DE BACKER

DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE

Behind DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE is LEEN DE BACKER.

See the full network in the app

Directors

According to the 2025 annual accounts

LEEN DE BACKER

Director

since 2023

Establishments

Establishment units

Physical locations of this company

Registered office

Kestelstraat 75

9880 Aalter

2.236.704.291

Bruggestraat 84

8700 Tielt

Active since 17 July 2014

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0556.697.054
VAT number: BE 0556.697.054
Registered office: Kestelstraat 75, 9880 Aalter
Names & denominations: DR. LEEN DE BACKER , MEDISCHE ONCOLOGIE
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 16 July 2014
Peppol: Active · Active since 27 Mar 2026
Activities · NACE: Activiteiten van medisch specialisten

View on CBE Public ↗ Annual accounts (NBB) ↗